Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Michael Gnant, Peter Dubsky et al.|Clinical Cancer Research|2019Cited by 77
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6Martin Filipits, Peter Dubsky, Margaretha Rudas et al.|ESMO Open|2021Cited by 25
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Richard Greil, Andreas Petzer et al.|Nature Cancer|2025Cited by 10
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.Christian F. Singer, Michael Gnant, Dominik Hlauschek et al.|Journal of Clinical Oncology|2024Cited by 6
mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohortMartin Filipits, Peter Dubsky, Margaretha Rudas et al.|Annals of Oncology|2018Cited by 4